REVIEW
Add like
Add dislike
Add to saved papers

Periorbital hemangiomas.

1. Any hemangioma that involves the upper or lower lid and leads to partial closure in infancy may interfere with or prevent development of normal binocular vision in a matter of days to weeks. 2. Hemangiomas least likely to interfere with vision are lower lid lesions occupying one third of the lid margin or less, not extending beyond the eyelid region, and resolving early. 3. Hemangiomas associated with deprivation amblyopia (with or without anisometropia) are lesions occupying more than one half of the lid margin, extending beyond the eyelid region, resolving late, and obstructing the visual axis. 4. Hemangiomas associated with isolated anisometropic amblyopia are local but bulky lesions that are usually but not always restricted to the upper lid, closing the eye partly and resolving late. 5. The treatment of choice for periorbital hemangiomas is corticosteroids, either systemic or intralesional.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app